HI
KPTI icon

HBK Investments’s Karyopharm Therapeutics KPTI Stock Holding History

HBK Investments’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,660
Closed -$679K – 1306
2018
Q3 		$679K Buy
+2,660
New +$735K 0.01% 845

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HBK Investments's KPTI Position: Q4 2018 in Review

HBK Investments sold out of Karyopharm Therapeutics (KPTI) in Q4 2018, closing a stake of 2,660 shares — an estimated $679K sold.

HBK Investments first reported a position in KPTI in Q3 2018 and held it in 1 quarter. The position peaked at $679K in Q3 2018. 115 funds tracked by Wall St. Rank hold KPTI as of Q4 2018.

  • HBK Investments reported no remaining Karyopharm Therapeutics position as of Q4 2018 after selling out during the quarter.
  • HBK Investments sold 2,660 Karyopharm Therapeutics shares in Q4 2018, an estimated $679K.
  • HBK Investments first reported a position in Karyopharm Therapeutics in Q3 2018 and held it in 1 quarter.
  • HBK Investments's Karyopharm Therapeutics position peaked at $679K in Q3 2018.
  • 115 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2018.

Based on HBK Investments's 13F filing for Q4 2018, filed 14 Feb 2019.